SIGLEC9

Across TCGA pan-cancer cohorts, SIGLEC9 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SIGLEC9 data layer compared with 24 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher SIGLEC9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SIGLEC9 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

COAD, LGG, and LUSC are the cancer types where SIGLEC9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	III,IV	0.159	0.692	.021	6	view →
LGG	DFS	Median	All	0.201	0.728	.011	3	view →
LUSC	DFS	Median	III,IV	0.249	0.661	.049	3	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
UCEC	DFS	Median	All	0.953	0.622	.034	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SIGLEC9–COAD (OS)

Open the COAD breakdown →